Shares of Histogenics Corp (NASDAQ:HSGX) were up 16.9% on Tuesday . The company traded as high as $0.29 and last traded at $0.20. Approximately 35,622,096 shares traded hands during trading, an increase of 354% from the average daily volume of 7,838,811 shares. The stock had previously closed at $0.17.

A number of analysts have recently weighed in on HSGX shares. Zacks Investment Research raised Histogenics from a “hold” rating to a “buy” rating and set a $0.25 price objective on the stock in a research report on Tuesday, January 15th. ValuEngine raised Histogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, HC Wainwright lowered Histogenics to a “hold” rating in a research report on Wednesday, January 2nd. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $2.44.

The company has a market capitalization of $20.01 million, a P/E ratio of -0.18 and a beta of 3.51.

In related news, major shareholder Randal J. Kirk sold 998,204 shares of the business’s stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $0.16, for a total transaction of $159,712.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Randal J. Kirk sold 251,800 shares of the business’s stock in a transaction on Friday, January 11th. The stock was sold at an average price of $0.17, for a total transaction of $42,806.00. The disclosure for this sale can be found here. Insiders own 19.70% of the company’s stock.

A hedge fund recently bought a new stake in Histogenics stock. Virtu Financial LLC acquired a new stake in Histogenics Corp (NASDAQ:HSGX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 213,352 shares of the biotechnology company’s stock, valued at approximately $117,000. Virtu Financial LLC owned approximately 0.73% of Histogenics at the end of the most recent reporting period. Institutional investors own 10.29% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/histogenics-hsgx-trading-up-16-9/2954060.html.

About Histogenics (NASDAQ:HSGX)

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Read More: Hedge Funds Explained

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.